Direct and Indirect Evidence for the Reversibility of Cirrhosis
Overview
Authors
Affiliations
The aim of this study was to assess the reversibility of cirrhosis after therapy in a large series of patients with cirrhosis from various etiologies. We performed a retrospective study of 113 patients with biopsy-proven cirrhosis who underwent specific therapy and follow-up biopsies. Two pathologists performed blinded analyses of indirect biochemical and morphological signs of cirrhosis. Fourteen (12.4%) of the 113 cirrhotic patients had biopsy-proven disappearance of cirrhosis, defined as a decrease of 2 or greater in their METAVIR fibrosis score: 8 were related to hepatitis C virus, 3 to hepatitis B virus, and 3 to autoimmune cirrhosis. Necro-inflammatory activity decreased from 2.4 +/- 0.65 to 0.85 +/- 0.9 (P = .004), and fibrosis from 4 to 1.7 +/- 0.61 (P = .001). Prothrombin time (n = 1), platelet count (n = 2), serum albumin level (n = 2), and ultrasound abnormalities (n = 6) normalized in patients who had initial abnormalities. Hyaluronic acid and procollagen type III serum level decreased in all. In the 11 patients with regression of viral cirrhosis, 2 were nonresponders and 9 were responders, including 2 relapsers. The 3 patients with regressive autoimmune cirrhosis were complete responders to immunosupressive therapy. Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease.
The strategy of laparoscopic surgery for asymptomatic antenatally diagnosed choledochal cyst.
Zhang X, Jin J, Qiu T, Zhou J, Che G, Ji Y BMC Surg. 2023; 23(1):204.
PMID: 37464354 PMC: 10354969. DOI: 10.1186/s12893-023-02095-3.
Texture Analysis of Gray-Scale Ultrasound Images for Staging of Hepatic Fibrosis.
Park E, Kim S, Park S, Baek T Taehan Yongsang Uihakhoe Chi. 2022; 82(1):116-127.
PMID: 36237456 PMC: 9432409. DOI: 10.3348/jksr.2019.0185.
Orr C, Wang P, Chen L, Wang T PLoS One. 2022; 17(5):e0267474.
PMID: 35552548 PMC: 9098014. DOI: 10.1371/journal.pone.0267474.
Liver fibrosis quantification.
Venkatesh S, Torbenson M Abdom Radiol (NY). 2022; 47(3):1032-1052.
PMID: 35022806 PMC: 9538706. DOI: 10.1007/s00261-021-03396-y.
Liver fibrosis assessment: MR and US elastography.
Ozturk A, Olson M, Samir A, Venkatesh S Abdom Radiol (NY). 2021; 47(9):3037-3050.
PMID: 34687329 PMC: 9033887. DOI: 10.1007/s00261-021-03269-4.